Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in previously untreated patients (PUPs) younger than 6 years of age with severe hemophilia A (baseline FVIII level < 1%) and < 3 exposure days to ADVATE, BAX 855 or plasma transfusion.